Zhong Chen, Soong-Hoon Kim, Stephanie A Barbosa, Tram Huynh, David R Tortolani, Kenneth J Leavitt, Donna D Wei, Veeraswamy Manne, Carolyn S Ricca, Johnni Gullo-Brown, Michael A Poss, Wayne Vaccaro, Mark E Salvati
Author Information
Zhong Chen: Bristol-Myers Squibb, Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543-4000, USA. zhong.chen@bms.com
The synthesis and SAR of a series of pyrrolopyridazine MEK inhibitors are reported. Optimal activity was achieved by incorporation of a 4-phenoxyaniline substituent at C4 and an acylated amine at C6.
